White House Unveils Plan to Cut Prescription-Drug Prices

September 9, 2021 by Dan McCue
White House Unveils Plan to Cut Prescription-Drug Prices
President Joe Biden speaks during an event in the East Room of the White House, Wednesday, Sept. 8, 2021, in Washington. (AP Photo/Evan Vucci)

WASHINGTON — The Biden administration on Thursday offered the first detailed look at actions the White House may take in conjunction with congressional action to lower prescription drug prices.

The 29-page plan, released through the Department of Health and Human Services, backs the intention of many congressional Democrats to enable the federal government to negotiate drug prices in Medicare and pass those lower prices on to consumers.

It would also permit drug importation from Canada, limit the ability of drug companies to raise prices on existing drugs and put a cap on out-of-pocket spending for the Medicare prescription drug benefit.

Overall, the administration is throwing its support behind price negotiation with drug manufacturers and limits on drug-price increases, promotion of industry competition, and scaled-up public and private research into new treatments.

The plan also calls for reducing regulatory barriers that may impede or slow the approval of lower-priced generics or licensing of biosimilars.

To help promote new drug innovations, the administration is also proposing the creation of a new agency at the National Institutes of Health.

But as broad as the announcement appears, it’s left at least one group of interested parties cold.

“What was released today is a laundry list of old partisan ideas and not a serious plan to address what patients pay out of pocket for prescription drugs,” said Stephen Ubl , president and CEO of PhRMA, a trade group for drug manufacturers. 

“What it leaves out is any attempt to fix a broken insurance system that discriminates against sick patients and does nothing to hold insurers and middlemen accountable for pocketing savings from our companies that should go to patients to lower their costs,” he said.

 The roll out of the prescription drug price plan came hours before the administration was set to announce it’s updated strategy for reining in the ongoing COVID-19 pandemic.

The administration says Americans pay too much for prescription drugs – more than $1,500 per person – and pay prices that are far higher than any comparable nation. 

In addition, it says, prices for brand name drugs are rising faster than inflation, and as a result, many Americans do not take medications as prescribed … with resulting harm to their health.

“Life-saving prescription medication should not cost anyone their life savings. Yet too often, many low-income families cannot take their prescription medications because of cost concerns,” said Health and Human Services Secretary Xavier Becerra in a written statement. 

“The Biden-Harris administration remains committed to making health care more affordable for American families, and this plan outlines one key way we will do that. By promoting negotiation, competition, and innovation in the health care industry, we will ensure cost fairness and protect access to care,” Becerra said.

The Drug Pricing Plan announced Thursday  responds to a request in an executive order the president signed in July, calling for “a plan to continue the effort to combat excessive pricing of prescription drugs and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such drugs, and to address the recurrent problem of price gouging.” 

The plan presents principles for equitable drug pricing reform through competition, innovation, and transparency; describes promising legislative approaches; and summarizes actions already underway or under consideration across HHS.

Most of the proposals included in the plan announced Thursday are not new, having been proposed by both House and Senate Democrats in past sessions of Congress. In some respects, the administration simply asks lawmakers to redouble those past efforts. 

Among other things, the White House is calling for legislation aimed at bringing generic and biosimilar drugs to market more quickly.

This could be done, it says, by shortening exclusivity periods, and creating incentives for doctors to prescribe biosimilars instead of brand-name drugs. 

But Democrats are hardly of one mind on the issue of prescription drug prices and remain divided over how far and how fast to go with any legislation to deal with it.

Republicans, meanwhile, are largely opposed to Medicare drug-price negotiations and have called for more bipartisan approaches to lower costs.

As for PhRMA’s Ubl, he said it’s “hard to ignore the irony that this is being released the same day the White House is unveiling a separate plan meant to regain control of the COVID-19 pandemic.”  

“The biopharmaceutical industry is continuing to work around the clock against this pandemic while this same White House is trying to make it more difficult for our industry to continue the fight against this pandemic and plan for future health crises,” he said.

A+
a-
  • Department of Health and Human Services
  • Joe Biden
  • Medicare
  • prescription drug prices
  • In The News

    Health

    Voting

    Prescription Drugs

    April 18, 2025
    by Dan McCue
    Scores of Generic Medications Recalled Over Quality Issues

    WASHINGTON — Nearly 40 different generic medications have been voluntarily recalled by Glenmark Pharmaceuticals after regulators flagged issues related to... Read More

    WASHINGTON — Nearly 40 different generic medications have been voluntarily recalled by Glenmark Pharmaceuticals after regulators flagged issues related to how the drugs were manufactured in India, the Food and Drug Administration announced Friday. To ensure the safety and uniformity of medicines, the FDA has imposed... Read More

    Pfizer Ends Development of Potential Pill Obesity Treatment

    Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level... Read More

    Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver... Read More

    The Skyrocketing Cost of Weight-Loss Drugs Has State Medicaid Programs Looking for a Solution

    States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to... Read More

    States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to get out from under the budgetary squeeze that took them by surprise. One solution some policymakers may try is restricting the number of people on Medicaid... Read More

    FDA Approves Painkiller Designed to Eliminate the Risk of Addiction Associated With Opioids

    WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of... Read More

    WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or... Read More

    January 29, 2025
    by Tom Ramstack
    Kennedy Downplays Vaccine Statements During Health Dept. Confirmation Hearing

    WASHINGTON — Robert F. Kennedy Jr. tried to deflect accusations of being a junk science advocate Wednesday during his Senate... Read More

    WASHINGTON — Robert F. Kennedy Jr. tried to deflect accusations of being a junk science advocate Wednesday during his Senate confirmation hearing to become secretary of the U.S. Department of Health and Human Services. Much of his time was spent defending his previous statements against vaccines... Read More

    J&J Buys Intra-Cellular in $14.6B Deal, Delving Further Into Central Nervous System Disorders

    Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders... Read More

    Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Monday that it will pay $132 in cash for each share of Intra-Cellular. That represents a 39%... Read More

    News From The Well
    scroll top